Skip to main content
Wee-Joo Chng on Muck Rack

Wee-Joo Chng

As seen in: Nature, NewsBreak
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Wee-Joo

Contact Wee-Joo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Final OS analyses from the TOURMALINE- MM3 and -MM4 RCTs of ixazomib maintenance in newly diagnosed multiple myeloma - Blood Cancer Journal

|
By Meletios A. Dimopoulos, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, Maria-Victoria Mateos, Kaveri Suryanarayan
| Nature Verified
Abstract TOURMALINE-MM3 (NCT02181413) and -MM4 (NCT02312258) were phase 3 studies of fixed-duration, single-agent ixazomib maintenance in post-transplant (TOURMALINE-MM3)/transplant-ineligible (TOURMALINE-MM4) patients with newly diagnosed multiple myeloma (NDMM) that demonstrated improved median progression-free survival (PFS) for ixazomib vs placebo. We present the final overall survival (OS) analyses for each study separately.
Open in Who Shared Issue with article?

A clinico-genomic prognostic model for primary myelodysplastic neoplasm in Asia - Blood Cancer Journal

|
By Harinder S. Gill, Melissa Ooi, Wee-Joo Chng, Hwei-Fang Tien, Hsin-An Hou, Lester Au
| Nature Verified
Abstract A personalized prognostic model that takes into account the unique molecular features of primary myelodysplastic neoplasm (MDS) in Asia patients is lacking. Diagnostic clinicopathologic features, cytogenetic changes, and gene mutations of ethnic Asian patients with primary MDS were analyzed. Variables were evaluated for associations with overall survival (OS), leukemia-free survival (LFS), and time to progression to secondary AML (TTP-sAML).
Open in Who Shared Issue with article?

Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720-1748 | Leukemia

|
By Rita Alaggio, Catalina Amador, Ioannis Anagnostopoulos, Ayoma D Attygalle, Emilio Berti, Govind Bhagat, Mariarita Calaminici, Amy Chadburn, Wah Cheuk, Wee-Joo Chng, John Choi, Shih-Sung Chuang, Sarah E. Coupland, Magdalena Czader, Sandeep Dave, Daphne de Jong, Ming-Qing Du, Kojo Elenitoba-Johnson, Judith A. Ferry, Julia T. Geyer, Dita A Gratzinger, Joan Guitart, Sumeet Gujral, Marian Harris, Christine Harrison, Sylvia Hartmann, Andreas Hochhaus Verified, Patty Jansen, Werner Kempf, Joseph Khoury, Hiroshi Kimura, Wolfram Klapper, Alexandra E. Kovach, Shaji Kumar Verified, Alexander J. Lazar, Stefano Lazzi, Lorenzo Leoncini, Nelson W. Y. Leung, Vasiliki Leventaki, Xiao-Qiu Li, Megan Lim Verified, Wei-ping Liu, Abner Louissaint Jr., Andrea Marcogliese, L. Jeffrey Medeiros, Michael Michal, Roberto N. Miranda, Christina Mitteldorf, Santiago Montes-Moreno, William Morice, Valentina Nardi, Kikkeri N. Naresh, Yasodha Natkunam, Siok-Bian Ng, Ilske Oschlies, German Ott, Marie Parrens, Melissa Pulitzer, S. Vincent Rajkumar, Andrew Rawstron, Karen L. Rech, Andreas Rosenwald, Clémentine Sarkozy, Caner Saygin, Anna Schuh, William Sewell, Reiner Siebert, Aliyah R. Sohani, Reuben M. Tooze, Alexandra Traverse-Glehen, Francisco Vega, Beatrice Vergier, Ashutosh D Wechalekar, Luc Xerri, Wenbin Xiao
| Nature Verified
Correction to: Leukemia https://doi.org/10.1038/s41375-022-01620-2, published online 22 June 2022 At the time of original publication, there was an incomplete listing of contributing authors and their institutions. This revision corrects those omissions. 1. Dr Ritsuro Suzuki, Department of Hematology & Oncology, Shimane University School of Medicine, Shimane, Japan, was regrettably omitted from the main author list; 2.
Open in Who Shared Issue with article?
See all 6 articles